GeneDx Strengthens Executive Leadership Team With Bryan Dechairo Named Chief Operating Officer
GeneDx Strengthens Executive Leadership Team With Bryan Dechairo Named Chief Operating Officer
As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program Management teams at GeneDx. He will be pivotal in driving operational excellence as the company enters the next phase of commercial growth.Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More
經驗豐富的診斷高管，擁有推動業務增長的良好記錄，負責產品與科技、運營、醫療事務、創新等多個領域
New Executive Leadership Positions Company for Growth and Scale
新任高管領導職務助力公司成長與擴展
STAMFORD, Conn.--(BUSINESS WIRE)--Jan. 2, 2025--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team.
康涅狄格州斯坦福--(商業資訊)--2025年1月2日--GeneDx（納斯達克：WGS），一家通過基因組洞察實現更好健康結果的領先公司，今日宣佈任命Bryan Dechairo爲首席運營官，即時生效。在新設立的職務中，Bryan將向首席執行官兼總裁Katherine Stueland彙報，並將作爲公司高管領導團隊的一員。
As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program Management teams at GeneDx. He will be pivotal in driving operational excellence as the company enters the next phase of commercial growth.
作爲首席運營官，布萊恩將監督GeneDx的產品與科技、運營、醫療事務、創新和項目管理團隊。他將在公司進入下一個商業增長階段時，發揮關鍵作用，推動運營卓越。
"Bryan's extensive clinical, technical and operational experience and proven ability to lead scalable transformations will play a pivotal role in helping us execute our strategic vision and accelerate the adoption of genomic insights across healthcare," said Stueland. "As we embark on the next phase of our growth and scale, I am confident Bryan's leadership will be critical in helping us deliver impactful genomic insights and improve health outcomes for an ever-growing number of patients and families."
Stueland表示："Bryan在臨牀、技術和運營方面的豐富經驗，以及他在可擴展轉型中的證明能力，將在幫助我們執行戰略願景和加速基因組洞察在醫療保健中的應用中發揮關鍵作用。隨着我們開始下一階段的成長與擴展，我相信Bryan的領導對幫助我們提供有影響力的基因組洞察和改善越來越多患者及其家庭的健康結果至關重要。"
Bryan brings over 30 years of experience in exploratory and commercial diagnostic businesses, driving the development of revenue-generating clinical innovations that enhance patient outcomes. He most recently served as President and CEO of Sherlock Biosciences, where he successfully transformed the company from a research-stage start-up into a commercial operation. Bryan has also held executive leadership roles at prominent diagnostic and pharmaceutical companies, including Pfizer, Myriad Genetics, Assurex, Medco Health and others. Bryan holds a PhD in Human Genetics from the University College of London and a BA in Integrative Biology from the University of California Berkeley.
Bryan在探索性和商業診斷業務方面擁有超過30年的經驗，推動收入生成型臨牀創新的發展，從而提升患者結果。他最近擔任Sherlock Biosciences的總裁兼首席執行官，成功將公司從研究階段的初創企業轉變爲商業運營。Bryan還曾在輝瑞、萬基遺傳、Assurex、Medco Health等知名診斷和藥品公司擔任高管領導職務。Bryan獲得倫敦大學學院人類遺傳學博士學位，並在加州大學伯克利分校獲得整合生物學學士學位。
"GeneDx has built a market-leading position in pediatric genetics and has an incredible opportunity to pave the way for the genomics revolution in healthcare today," said Dechairo. "With world-class products, advanced AI and the most dynamic minds in the industry, I'm looking forward to supercharging operational excellence to accelerate profitable growth."
「GeneDx在兒童遺傳學領域建立了市場領先地位，並有着不可思議的機會爲今天醫療保健中的基因組革命鋪平道路，」Dechairo說。「憑藉世界級的產品、愛文思控股的人工智能和行業中最具活力的人才，我期待着增強事件控制項的卓越性，以加速盈利增長。」
About GeneDx:
關於GeneDx:
GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world's largest, rare disease data sets. For more information, please visit and connect with us on LinkedIn, Facebook, and Instagram.
GeneDx（納斯達克：WGS）提供個性化和可操作的健康見解，以幫助診斷、指導治療和改善藥物發現。該公司獨特的定位加速了基因組和大規模臨牀信息的使用，使精準醫療成爲護理的標準。GeneDx處於通過其行業領先的外顯子組和基因組測試及解讀服務來轉變醫療保健的前沿，依託於世界上最大的罕見疾病數據集。欲了解更多信息，請訪問並在LinkedIn、Facebook和Instagram上與我們聯繫。
View source version on businesswire.com:
在businesswire.com查看源版本：
Press@genedx.com
Investors@genedx.com
Press@genedx.com
Investors@genedx.com
Source: GeneDx
來源：GeneDx
譯文內容由第三人軟體翻譯。
